Trials / Completed
CompletedNCT03362931
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | XEN45 | XEN45 unilaterally implanted in the study eye |
Timeline
- Start date
- 2018-07-19
- Primary completion
- 2022-03-18
- Completion
- 2022-03-18
- First posted
- 2017-12-05
- Last updated
- 2023-05-17
- Results posted
- 2023-05-17
Locations
16 sites across 6 countries: Australia, Canada, Singapore, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03362931. Inclusion in this directory is not an endorsement.